Description
LY294002 is an inhibitor of PI3K that is used to sensitize cancer cells to other co-administered anticancer chemotherapeutics. In macrophages and monocytes, LY294002 inhibits NF-κB activity and decreases levels of p50 NF-κB; it also inhibits LPS-induced expression of IL-10. LY294002 prevents ruffled border formation in osteoclasts by altering the binding of acidic vacuoles with the intercellular membrane. Additionally, this compound inhibits DNA-dependent protein kinase (DPK) activity and prevents the formation of NO.